Diagenix

Recruiting

Precision Obesity Medicine: Genetic Prediction of Response to GLP-1/GIP Agonists.

Prediction of Response to GLP-1/GIP Receptor Agonists in Obesity Using Genetic Risk Score and SNP Profiling: A Prospective Cohort Study.

Lead sponsor

National and Kapodistrian University of Athens

Assets

Semaglutide / Tirzepatide

Listed sites

Recruiting sites

Enrollment

220

estimated

Study population

Obesity / overweight

Key I/E criterion

•BMI ≥40

Primary endpoint

•Percentage weight loss

Footprint

Where this trial recruits

Site locations as reported to ClinicalTrials.gov. Site count is not enrollment count; per-site enrollment is not available from source.

Identifiers

Registered as

NCT IDNCT07653412

Org study ID5002

Timeline

Milestones

Study start2026-04-22actual

Study first posted2026-06-17actual

Last update posted2026-06-17actual

Primary completion2027-01-30estimated

Study completion2027-06-30estimated

Assets

Investigational agents

Semaglutide Tirzepatide

Study populations

Who this study enrolls

Obesity / overweight

Eligibility

Who can enroll

Minimum age18 Years

SexAll

Healthy volunteersNot accepted

Sampling methodNon probability sample

Study population text

Adults with obesity receiving semaglutide or tirzepatide as part of routine clinical care. Participants will undergo clinical, biochemical, and genetic assessment and will be followed prospectively for six months to evaluate the association between genetic risk score, obesity-related genetic variants, and weight loss response.

Inclusion criteria

Age ≥18 years BMI ≥40 kg/m² or ≥37 kg/m² with comorbidities Initiation of semaglutide or tirzepatide

Exclusion criteria

Prior bariatric surgery Secondary causes of obesity Active malignancy Chronic pancreatitis Family history of medullary thyroid carcinoma

Endpoints (1)

What's being measured

Protocol endpoints and posted registry outcome measures, grouped into outcome categories. Composite endpoints show their component event types. Standard codes (LOINC, SNOMED CT) are shown where available.

Weight & body composition

1 endpoint

Primary/protocol endpoint

Percentage weight loss at 6 months

Time frame:6 months

descriptive

Publications (8)

Bibliography

Records linked to this trial through ClinicalTrials.gov references, PubMed NCT search, and curated study seeds. 'Canonical' marks design/result papers; others are registry references or candidates.

Registry references + supporting bibliography

Provenance

Sources

Trial identity, design, statusClinicalTrials.gov API v2

Snapshot dateJuly 1, 2026

Endpoint classificationDelfa endpoint taxonomy v2 (May 13, 2026)

Results tableno registry results posted yet

Trial facts come from public ClinicalTrials.gov records. Endpoint categories are Delfa's classification of those records, not a ClinicalTrials.gov field. All figures reflect the July 1, 2026 snapshot.